These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Endothelin and the tumorigenic component of bone cancer pain. Peters CM; Lindsay TH; Pomonis JD; Luger NM; Ghilardi JR; Sevcik MA; Mantyh PW Neuroscience; 2004; 126(4):1043-52. PubMed ID: 15207337 [TBL] [Abstract][Full Text] [Related]
4. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Sevcik MA; Luger NM; Mach DB; Sabino MA; Peters CM; Ghilardi JR; Schwei MJ; Röhrich H; De Felipe C; Kuskowski MA; Mantyh PW Pain; 2004 Sep; 111(1-2):169-80. PubMed ID: 15327821 [TBL] [Abstract][Full Text] [Related]
5. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Kundu N; Fulton AM Cancer Res; 2002 Apr; 62(8):2343-6. PubMed ID: 11956094 [TBL] [Abstract][Full Text] [Related]
7. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526 [TBL] [Abstract][Full Text] [Related]
8. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Tomozawa S; Nagawa H; Tsuno N; Hatano K; Osada T; Kitayama J; Sunami E; Nita ME; Ishihara S; Yano H; Tsuruo T; Shibata Y; Muto T Br J Cancer; 1999 Dec; 81(8):1274-9. PubMed ID: 10604722 [TBL] [Abstract][Full Text] [Related]
10. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613 [TBL] [Abstract][Full Text] [Related]
12. A mechanism-based understanding of bone cancer pain. Mantyh PW Novartis Found Symp; 2004; 261():194-214; discussion 214-9, 256-61. PubMed ID: 15469052 [TBL] [Abstract][Full Text] [Related]
13. Involvement of the spinal NMDA receptor/PKCγ signaling pathway in the development of bone cancer pain. Xiaoping G; Xiaofang Z; Yaguo Z; Juan Z; Junhua W; Zhengliang M Brain Res; 2010 Jun; 1335():83-90. PubMed ID: 20362561 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms that generate and maintain bone cancer pain. Mantyh PW; Hunt SP Novartis Found Symp; 2004; 260():221-38; discussion 238-40, 277-9. PubMed ID: 15283453 [TBL] [Abstract][Full Text] [Related]
15. Intrathecal injection of metabotropic glutamate receptor subtype 3 and 5 agonist/antagonist attenuates bone cancer pain by inhibition of spinal astrocyte activation in a mouse model. Ren BX; Gu XP; Zheng YG; Liu CL; Wang D; Sun YE; Ma ZL Anesthesiology; 2012 Jan; 116(1):122-32. PubMed ID: 22123524 [TBL] [Abstract][Full Text] [Related]
17. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747 [TBL] [Abstract][Full Text] [Related]
18. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220 [TBL] [Abstract][Full Text] [Related]
19. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. Katagiri M; Ogasawara T; Hoshi K; Chikazu D; Kimoto A; Noguchi M; Sasamata M; Harada S; Akama H; Tazaki H; Chung UI; Takato T; Nakamura K; Kawaguchi H J Bone Miner Res; 2006 Feb; 21(2):219-27. PubMed ID: 16418777 [TBL] [Abstract][Full Text] [Related]
20. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Furuse S; Kawamata T; Yamamoto J; Niiyama Y; Omote K; Watanabe M; Namiki A Anesthesiology; 2009 Jul; 111(1):173-86. PubMed ID: 19512863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]